Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schilsky, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schilsky, R. L.
Clinical Cancer Research Vol. 8, 935-938, April 2002
© 2002 American Association for Cancer Research

Editorial

End Points in Cancer Clinical Trials and the Drug Approval Process1

Richard L. Schilsky2

Medicine and Associate Dean for Clinical Research, Biological Sciences Division, University of Chicago, Chicago, Illinois 60637

ABSTRACT

The sequencing of the human genome and the elucidation of many molecular pathways important in cancer cell proliferation, apoptosis, and metastasis have provided unprecedented opportunities for development of new agents to prevent and treat cancer. The types of molecules in development are increasingly varied and include small molecules, monoclonal antibodies, antisense oligonucleotides, and ribozymes. Thus, the variety of anticancer agents in clinical development is now greater than ever before, and the number of agents currently in clinical trial for various cancer indications is estimated to exceed 400. Many of these drugs would be expected to work in only narrowly defined patient populations that must be prospectively identified. Thus, the development of the therapeutic agent must often be linked to the development of a molecular diagnostic product. Drugs that produce primarily cytostatic effects might not be expected to produce regression of tumor masses; thus, evaluation of such agents would best be done in populations of patients with low tumor burdens but high risk of disease progression. As traditional clinical end points prove more difficult to apply in evaluation of molecularly targeted therapies, a great need exists to define and validate surrogate markers of effect and of benefit. New clinical trial designs and end points are necessary to permit more efficient evaluation of putative cancer treatments. This editorial will review commonly used clinical trial end points and describe their potential advantages and disadvantages to expedite the drug approval process required in the United States.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Hazarika, X. Jiang, Q. Liu, S.-L. Lee, R. Ramchandani, C. Garnett, M. S. Orr, R. Sridhara, B. Booth, J. K. Leighton, et al.
Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib
Clin. Cancer Res., September 1, 2008; 14(17): 5325 - 5331.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom
Interaction of Imatinib with Human Organic Ion Carriers
Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Brave, V. Goodman, E. Kaminskas, A. Farrell, W. Timmer, S. Pope, R. Harapanhalli, H. Saber, D. Morse, J. Bullock, et al.
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Clin. Cancer Res., January 15, 2008; 14(2): 352 - 359.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom
Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib
Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Lefranc, V. Facchini, and R. Kiss
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Oncologist, December 1, 2007; 12(12): 1395 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Rock, D. L. Kennedy, M. H. Furness, W. F. Pierce, R. Pazdur, and L. B. Burke
Patient-Reported Outcomes Supporting Anticancer Product Approvals
J. Clin. Oncol., November 10, 2007; 25(32): 5094 - 5099.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Milowsky, D. M. Nanus, L. Kostakoglu, C. E. Sheehan, S. Vallabhajosula, S. J. Goldsmith, J. S. Ross, and N. H. Bander
Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors
J. Clin. Oncol., February 10, 2007; 25(5): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami
Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 44 - 48.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. U. Lin, S. Sarantopoulos, J. R. Stone, I. Galinsky, R. M. Stone, D. J. Deangelo, and R. J. Soiffer
Fatal hepatic necrosis following imatinib mesylate therapy
Blood, November 1, 2003; 102(9): 3455 - 3456.
[Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. S H Lam and R. J Ignoffo
A guide to clinically relevant drug interactions in oncology
Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85.
[Abstract] [PDF]

Home page
 JCOHome page
A. W. Tolcher, C. H. Takimoto, and E. K. Rowinsky
The Multifunctional, Multi-Institutional, and Sometimes Even Global Phase I Study: A Better Life for Phase I Evaluations or Just "Living Large"?
J. Clin. Oncol., November 1, 2002; 20(21): 4276 - 4278.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, et al.
Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
Clin. Cancer Res., October 1, 2002; 8(10): 3034 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Oncologist, October 1, 2002; 7(5): 393 - 400.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.